文献速递糖尿病

达格列净或沙格列汀治疗儿童2型糖尿病后的安全性、生长与发育(T2NOW随访)

Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up).
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

T2NOW的多中心随机双盲3期试验纳入210例10至17岁2型糖尿病儿童,先接受达格列净、沙格列汀或安慰剂治疗52周,再随访52周。停药后随访期间,各组身高、体重、BMI、Tanner分期、生长与成熟标志物、骨标志物及不良事件比例相似,未提出新的安全性问题。

要点

  • 停药后52周随访中,达格列净组18.5%、沙格列汀组15.9%与安慰剂组21.1%的患者报告至少1次不良事件,组间相似。
  • 身高和体重从基线至第104周轻度增加,BMI总体稳定,各治疗组变化相似。
  • 性成熟正常进展,Tanner分期变化及生长、成熟和骨标志物在各组间相似,无死亡发生。

核心结论

  • 既往接受达格列净或沙格列汀治疗52周的儿童2型糖尿病患者,在停药后随访至52周时,身高、体重、BMI、Tanner分期、生长与成熟标志物、骨标志物或不良事件方面未提出安全性问题。

研究设计与样本

  • 多中心、随机、双盲3期试验(T2NOW),纳入210例10至17岁2型糖尿病儿童,先接受每日一次达格列净(5、10 mg)、沙格列汀(2.5、5 mg)或安慰剂联合饮食、运动、二甲双胍和/或胰岛素治疗52周,随后进行52周非治疗随访。

主要发现

  • 从基线至第104周,平均身高和体重轻度增加,BMI总体稳定,各治疗组变化相似。
  • 至第104周性成熟正常进展,Tanner分期变化及生长与成熟标志物、骨标志物变化在各组间相似。
  • 非治疗随访期间报告至少1次不良事件的患者比例:既往达格列净组18.5%、沙格列汀组15.9%,安慰剂组21.1%,组间相似。
  • 无死亡发生。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The T2NOW trial of dapagliflozin or saxagliptin vs placebo in pediatric patients with type 2 diabetes (T2D) demonstrated promising efficacy data for dapagliflozin and did not raise any safety concerns over 52 weeks. OBJECTIVE: This work aimed to assess long-term effects of prior dapagliflozin/saxagliptin administration on safety, growth, and development. METHODS: A multicenter, randomized, double-blind phase 3 trial (T2NOW) was conducted among 210 children with T2D aged 10 to 17 years, followed for up to 1 year after treatment. Participants were previously treated with once-daily dapagliflozin (5, 10 mg), saxagliptin (2.5, 5 mg), or placebo as an add-on to diet, exercise, metformin, and/or insulin for 52 weeks, plus a 52-week nontreatment follow-up period. Main outcome measures included change in height, weight, body mass index (BMI), Tanner staging, growth and maturation markers, bone biomarkers, and adverse events (AEs) from baseline to week 104. RESULTS: As expected in a pediatric population, mean height and weight slightly increased from baseline to week 104. BMI remained generally stable; changes were similar across treatment groups. Sexual maturation progressed normally to week 104, with similar shifts between Tanner stages and changes in growth and maturation markers and bone biomarkers across groups. The proportion of patients reporting 1 or more AEs during the nontreatment follow-up period was similar across groups previously treated with dapagliflozin (18.5%) or saxagliptin (15.9%) compared to placebo (21.1%). No deaths occurred. CONCLUSION: Prior treatment with dapagliflozin or saxagliptin for 52 weeks did not raise any safety concerns relating to height, weight, BMI, Tanner staging, growth and maturation markers, bone biomarkers, or AEs for up to 52 weeks following treatment discontinuation in pediatric patients with T2D.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Shehadeh N, Galassetti P, Iqbal N, et al. Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up). J Clin Endocrinol Metab. 2025. PMID: 39446459. doi:10.1210/clinem/dgae723

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。